Multiple sclerosis: New perspectives on the patient journey

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Bruce S. Pyenson, Tia Goss Sawhney, Michele M. Berrios, Samantha Tomicki | 28 April 2017

This report examines the multiple sclerosis population in Medicare Part D. Study results include characteristics of enrollees using disease-modifying therapies (DMTs) and show how cost sharing and therapies differed by demographic and coverage characteristics. Due to the cost of DMT, beneficiaries not receiving the low-income subsidy or employer-sponsored coverage may have to pay large out-of-pocket amounts. This study also examines the use of MS-related, non-DMT drugs to treat MS-related conditions.

This report was commissioned by Biogen.

Authors